Pulmatrix, Inc. (NASDAQ:PULM) Sees Significant Decline in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) saw a large decrease in short interest during the month of August. As of August 15th, there was short interest totaling 9,800 shares, adecreaseof42.7% from the July 31st total of 17,100 shares. Based on an average daily volume of 30,400 shares, the days-to-cover ratio is currently 0.3 days. Currently,0.3% of the company’s shares are short sold. Currently,0.3% of the company’s shares are short sold. Based on an average daily volume of 30,400 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen started coverage on shares of Pulmatrix in a research note on Tuesday, May 20th. They set a “sell” rating on the stock.

Institutional Investors Weigh In On Pulmatrix

An institutional investor recently raised its position in Pulmatrix stock. SBI Securities Co. Ltd. raised its stake in shares of Pulmatrix, Inc. (NASDAQ:PULM) by 15.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,565 shares of the biotechnology company’s stock after purchasing an additional 8,208 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 11.84% of the company’s stock.

Pulmatrix Trading Up 1.7%

Shares of PULM stock opened at $4.87 on Monday. The firm has a 50-day moving average of $5.55 and a 200-day moving average of $6.53. Pulmatrix has a one year low of $1.78 and a one year high of $10.40.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 97.25% and a negative net margin of 122.46%.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.